Navigation Links
New Investors Fund Expansion of Cavidi AB
Date:11/16/2007

Funding to Lead to Improved HIV Management in Developing World

UPPSALA, Sweden, November 16 /PRNewswire/ -- Cavidi AB announced today that it has signed an agreement with a consortium of American and Swedish investors. The consortium has provided over US$1.0 million of operational funding, and has committed to raising additional funding as necessary. The capital will be used to drive forward Cavidi's newly adopted three-year business plan. Cavidi is the producer of ExaVir(TM) Load, an HIV viral load assay suited for resource-limited settings.

Viral load monitoring is essential for the proper management of HIV-infected patients being treated with antiretroviral drugs (ARVs). The test helps doctors use ARVs more effectively, extending a patient's length and quality of life, limiting the development of viral resistance and minimizing waste of medication.

The key members of the investment consortium include several American investors experienced in venture capital markets as well as senior Cavidi management. The three-year plan they are funding seeks to generate more than a five-fold growth in revenue. It will capitalize on the recent release of Cavidi's ExaVir Load Version 3 - a new and improved version of their HIV viral load assay. It is also part of the plan to appoint additional distributors in Asia. Further investment will be required in both working capital and equipment in order to undertake a major expansion in production capacity.

The consortium will appoint a new member to Cavidi's Board of Directors. They have also committed to raising additional capital over the life of the three-year plan as needed.

"This is an important step forward for Cavidi," said Martyn Eales, the company's CEO. "It gives us additional resources to fully promote the new version of ExaVir Load." Cavidi is also on the verge of finalizing agreements with major international non-government organizations, as well as new distributors in Africa and Asia. This will ensure their ability to capitalize on the the growing acceptance of leading HIV clinicians worldwide of viral load monitoring as an essential part of effective HIV management. "The easy-to-use, affordable and accurate HIV viral load monitoring that ExaVir Load provides is especially needed in resource-limited environments," said Eales. "It permits the optimal use of what is invariably a limited supply of ARVs."

He went on to say Cavidi expects a rapid increase in sales of ExaVir Load assay kits due to these new testing strategies as they incorporate viral load monitoring as an essential part of HIV management wherever it is provided.

About Cavidi AB

Cavidi's mission is to make medical diagnostics more accessible in those parts of the orld where resources and infrastructure are limited. Their products include ExaVir Load which is used to quantify the amount of HIV in a patient's blood, and ExaVir Drug which measures a patient's resistance to ARVs. Cavidi was founded by leading virologists at Uppsala University in Sweden in 1984.

http://www.cavidi.com


'/>"/>
SOURCE Cavidi AB
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at JMP Securities Sector Focus Conference
2. Paramount Acquisition Corp. Announces Chem Rx Expansion into Albany, New York Market
3. The Arthur M. Blank Family Foundation Pushes for Pre-K Expansion in Georgia
4. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
5. LehmanMillet Continues Expansion with Strategic Hires
6. U.S. Reps. Oberstar and Walz Discuss DM&E Railroad Expansion With Rochester, Minn. Leaders
7. AARP Calls on Governor Schwarzenegger to Discourage Veto of SCHIP Expansion Bill
8. Illinois AARP Presses for Expansion of Childrens Health Insurance Program (SCHIP)
9. Expansion and Growth Spur INSPIRIS Executive Leadership Promotions
10. Susan G. Komen for the Cure Launches Unprecedented Global Expansion Program in 10 Countries
11. Chemizon Announces Research Collaboration Expansion With Takeda
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... Center for Autism and Related Disorders (CARD) ... by autism spectrum disorder (ASD) and other developmental disabilities. The group, which is being ... and other caregivers the opportunity to share stories and advice, seek help, and continue ...
(Date:12/2/2016)... ... 02, 2016 , ... Dr. Raffi Hovsepian, a leading plastic, ... 2016 “Guide to America’s Top Plastic Surgeons” for seven consecutive years. The prestigious ... experience, and professional associations. , One the most frequently honored surgeons in ...
(Date:12/2/2016)... ... December 02, 2016 , ... Universal Medical ... systems and the first company to offer robotic imaging to veterinary medicine is ... booth # 941 for the American Association of Equine Practitioners 62nd Annual Convention ...
(Date:12/2/2016)... San Francisco, CA (PRWEB) , ... December 02, ... ... in digitally-enabled care journeys, announced today that it has raised $6.0 million in ... are inspired by Clarify Health’s conviction that patients and their caregivers can receive ...
(Date:11/30/2016)... Massachusetts (PRWEB) , ... November 30, 2016 , ... ... proud to announce that we have been designated as a Cigna Infertility Center ... or exceed rigorous performance standards. , “It’s an honor to be designated ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... , Dec. 1, 2016  Today, Simpson Healthcare Executives, ... honor of being selected as winners of multiple awards ... Executives Website at the PLATINUM level, Blue Zones Menu ... at the GOLD Level, and our proprietary 3ConneX Platform ... Simpson Healthcare Executives, we are excited to showcase our ...
(Date:12/2/2016)... Allergan plc (NYSE: AGN ), a ... previously announced Accelerated Share Repurchase (ASR) Program. Logo - ... ... previously announced, the Company entered into a variable tenor ASR ... repurchase $10 billion of its ordinary shares. Approximately 40.5 million ...
(Date:11/30/2016)... 2016 Research and Markets has announced the ... MedCore" report to their offering. ... , Detachable coil embolization is ... malformations. The detachable coil embolization treatment of cerebral aneurysms is less invasive ... weakened area in the wall of an artery in the brain. This ...
Breaking Medicine Technology: